Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, open-label compassionate use program in cystic fibrosis patients with non-tuberculous mycobacteria (NTM) Infection

Trial Profile

A prospective, open-label compassionate use program in cystic fibrosis patients with non-tuberculous mycobacteria (NTM) Infection

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Cystic fibrosis; Nontuberculous mycobacterium infections
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 15 Jul 2019 According to a Beyond Air media release, the company has changed its name from AIT Therapeutics to Beyond Air.
    • 16 Jul 2018 According to an AIT Therapeutics media release, data from the compassionate use study was presented at the 3rd Annual World Bronchiectasis Conference.
    • 27 Jun 2018 According to an AIT Therapeutics media release, data from compassionate use study will be presented at the 3rd Annual World Bronchiectasis Conference.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top